EDAP TMS S.A. Files 6-K Report

Ticker: EDAP · Form: 6-K · Filed: Nov 18, 2025 · CIK: 1041934

Edap Tms SA 6-K Filing Summary
FieldDetail
CompanyEdap Tms SA (EDAP)
Form Type6-K
Filed DateNov 18, 2025
Risk Levellow
Pages11
Reading Time14 min
Key Dollar Amounts$5,084, $9,247, $12,992, $10,411, $763
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer

TL;DR

EDAP TMS S.A. filed a 6-K on Nov 18, 2025, confirming its foreign private issuer status. Nothing major, just routine compliance.

AI Summary

EDAP TMS S.A. filed a Form 6-K on November 18, 2025, to report its status as a foreign private issuer. The filing includes standard disclosures and signatures, with Ken Mobeck, Chief Financial Officer, signing on behalf of the company. The report indicates EDAP TMS S.A. is the global leader in therapeutic ultrasound.

Why It Matters

This filing provides routine updates for investors and regulatory bodies, confirming EDAP TMS S.A.'s status and adherence to reporting requirements as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine filing confirming the company's status and does not contain new financial or operational information that would typically indicate increased risk.

Key Players & Entities

  • EDAP TMS S.A. (company) — Registrant
  • Ken Mobeck (person) — Chief Financial Officer
  • November 18, 2025 (date) — Filing Date

FAQ

What is the purpose of this Form 6-K filing by EDAP TMS S.A.?

The Form 6-K filed on November 18, 2025, serves as a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Who signed this report on behalf of EDAP TMS S.A.?

Ken Mobeck, Chief Financial Officer, signed the report on behalf of EDAP TMS S.A. on November 18, 2025.

Does EDAP TMS S.A. file annual reports under Form 20-F or Form 40-F?

Yes, EDAP TMS S.A. indicates it files annual reports under cover of Form 20-F.

What is EDAP TMS S.A.'s primary business area as indicated in the filing?

The filing identifies EDAP TMS S.A. as the Global Leader in Therapeutic Ultrasound and its Standard Industrial Classification is ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845].

What is the filing date and period of report for this 6-K?

The filing date and conformed period of report is November 18, 2025.

Filing Stats: 3,414 words · 14 min read · ~11 pages · Grade level 9.8 · Accepted 2025-11-18 06:05:13

Key Financial Figures

  • $5,084 — 2025 Site of Service CPT Code Procedure $5,084 (1) Standard OR 55875 Prostate Brachyth
  • $9,247 — tandard OR 55875 Prostate Brachytherapy $9,247 (1) Standard OR 55873 Cryo Ablation $12
  • $12,992 — 247 (1) Standard OR 55873 Cryo Ablation $12,992 (1) Specialized MRI Suite C9734 / 55882
  • $10,411 — ation $9,247 (1) Standard OR 55880 HIFU $10,411 (1) Standard OR 55866 Laparoscopic Pros
  • $763 — Work RVU (2025) (2) CPT Code Procedure $763 13.46 55875 Prostate Brachytherapy $744
  • $744 — $763 13.46 55875 Prostate Brachytherapy $744 13.60 55873 Cryo $579 11.50 55882 MRI T
  • $579 — ate Brachytherapy $744 13.60 55873 Cryo $579 11.50 55882 MRI Transurethral Ultrasoun
  • $951 — 2 MRI Transurethral Ultrasound Ablation $951 17.73 55880 HIFU $1,157 22.46 55866 Lap
  • $1,157 — trasound Ablation $951 17.73 55880 HIFU $1,157 22.46 55866 Laparoscopic Prostatectomy
  • $4.9M — ) (0.19) Earnings (Loss) Per Share HIFU $4.9M HIFU $7.7M +57% 3 months 2024 3 months
  • $7.7M — rnings (Loss) Per Share HIFU $4.9M HIFU $7.7M +57% 3 months 2024 3 months 2025 $ 1 4
  • $6.3M — 3 months 2025 $ 1 4 . 4 M Distribution $6.3M - 14% Distribution $7.3M ESWL $2.1M - 4
  • $7.3M — M Distribution $6.3M - 14% Distribution $7.3M ESWL $2.1M - 4% ESWL $2.2M NOTE: Transl
  • $2.1M — ion $6.3M - 14% Distribution $7.3M ESWL $2.1M - 4% ESWL $2.2M NOTE: Translated for co
  • $2.2M — Distribution $7.3M ESWL $2.1M - 4% ESWL $2.2M NOTE: Translated for convenience of the

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 18, 2025 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER The Global Leader in Therapeutic Ultrasound 1 Company Overview 3 Strategic Company Focus 4 Global Leader in Therapeutic Ultrasound for the Treatment of Cancer and Benign Disease Investment Thesis: Strong Growth Opportunity 5 x Large and Growing Market Opportunity: Urology and Prostate Cancer x Solves an Important Unmet Clinical Need in Cancer x Proven Compelling Clinical Evidence x Increasing Patient and Physician Demand x Strong Hospital and Physician Reimbursement x Leverages Current Advancements in Imaging, AI, and Robotics x Growing Worldwide Install Base x Ideally Positioned for Expanded Indications (BPH, Endometriosis, Other) 350+ Focal One Robotic H FU Clinical Sites Large and Growing Market Opportunity In Urology and Prostate Cancer 7 3.3 Million American Men Living with Prostate Cancer in the U.S. (1) 313,780 New Cases Diagnosed in the U.S. (1) 35,770 U.S. Deaths from Prostate Cancer (1) U . S . P R O S T A T E C A N C E R M A R K E T Prostate Cancer is the Most Common Cancer Amongst Men In the U.S. Prostate (1) 2025 estimates from the American Cancer Society ( www.cancer.org ) 8 Lung & Bronchus Colorectum Skin Urinary Bladder New Cases Deaths Prostate Cancer Market Opportunity Number of New Prostate Cancer Cases Region 473,011 Europe 386,424 Asia 255,782 North America 225,985 Latin America 103,050 Africa 23,602 Oceania 1,467,854 Total L A R G E G L O B A L M A R K E T 1.5 Million New Prostate Cancer Cases Per Year 9 Data Source: Cases refers to Diagnosed Cases per year From World Health Organization – Globocan 2022 Focal One Answers an Unmet Need for a Large Underserved Patient Population P R O S TA TE C A N C E

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.